Udo Lindig

3.5k total citations
36 papers, 298 citations indexed

About

Udo Lindig is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Udo Lindig has authored 36 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 14 papers in Surgery. Recurrent topics in Udo Lindig's work include Gastric Cancer Management and Outcomes (22 papers), Gastrointestinal Tumor Research and Treatment (13 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Udo Lindig is often cited by papers focused on Gastric Cancer Management and Outcomes (22 papers), Gastrointestinal Tumor Research and Treatment (13 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Udo Lindig collaborates with scholars based in Germany, Switzerland and Australia. Udo Lindig's co-authors include Eray Goekkurt, Sylvie Lorenzen, Ralf‐Dieter Hofheinz, Peter Thuss‐Patience, Jorge Riera Knorrenschild, Claudia Pauligk, Thomas J. Ettrich, Albrecht Kretzschmar, Nils Homann and Georg Martin Haag and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Hepatology and Annals of Oncology.

In The Last Decade

Udo Lindig

33 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Udo Lindig Germany	10	210	181	134	83	31	36	298
Yuriy Ostapenko Ukraine	3	149 0.7×	131 0.7×	73 0.5×	62 0.7×	23 0.7×	6	227
Yutaka Asakuma Japan	8	155 0.7×	97 0.5×	152 1.1×	83 1.0×	10 0.3×	18	279
Masaki Wato Japan	11	140 0.7×	100 0.6×	179 1.3×	66 0.8×	8 0.3×	40	291
Sejung Park South Korea	10	151 0.7×	155 0.9×	120 0.9×	40 0.5×	32 1.0×	22	274
Junfeng Zhou China	9	203 1.0×	100 0.6×	114 0.9×	137 1.7×	35 1.1×	18	350
Tadayoshi Hashimoto Japan	10	170 0.8×	95 0.5×	161 1.2×	35 0.4×	38 1.2×	39	277
Kanwal Pratap Singh Raghav United States	5	117 0.6×	163 0.9×	61 0.5×	89 1.1×	41 1.3×	8	245
K.-W. Lee South Korea	7	242 1.2×	252 1.4×	131 1.0×	121 1.5×	25 0.8×	16	378
Jen‐Hao Chen Taiwan	9	320 1.5×	76 0.4×	198 1.5×	141 1.7×	45 1.5×	10	415
Etsuro Bando Japan	5	214 1.0×	70 0.4×	194 1.4×	141 1.7×	15 0.5×	6	333

Countries citing papers authored by Udo Lindig

Since Specialization

Citations

This map shows the geographic impact of Udo Lindig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Udo Lindig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Udo Lindig more than expected).

Fields of papers citing papers by Udo Lindig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Udo Lindig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Udo Lindig. The network helps show where Udo Lindig may publish in the future.

Co-authorship network of co-authors of Udo Lindig

This figure shows the co-authorship network connecting the top 25 collaborators of Udo Lindig. A scholar is included among the top collaborators of Udo Lindig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Udo Lindig. Udo Lindig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lorenzen, Sylvie, Alexandra Stein, Udo Lindig, et al.. (2025). 2122P Objective response to sacituzumab-govitecan (SG) in patients with metastatic esophagogastric adenocarcinoma in second-line or beyond: Primary endpoint analysis of the SAGA phase Ib/II trial (AIO-STO-0123/ass, UCCL-IKF-SAGA/IKF065). Annals of Oncology. 36. S1115–S1115.

Müller, Christa E., Alicia C Marín, Raphael Mohr, et al.. (2025). Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population. Journal of Cancer Research and Clinical Oncology. 151(6). 191–191.

Al‐Batran, Salah‐Eddin, Thorsten Oliver Goetze, Peter Thuss‐Patience, et al.. (2024). Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy. International Journal of Cancer. 154(12). 2142–2150. 5 indexed citations

Lorenzen, Sylvie, Thorsten Oliver Goetze, Peter Thuss‐Patience, et al.. (2024). LBA59 Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial. Annals of Oncology. 35. S1249–S1250. 2 indexed citations

Vogel, Arndt, Anna Saborowski, Gabriele Margareta Siegler, et al.. (2023). 955P IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma. Annals of Oncology. 34. S598–S598. 1 indexed citations

Lorenzen, Sylvie, Peter Thuss‐Patience, Jorge Riera Knorrenschild, et al.. (2022). 1203O FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO. Annals of Oncology. 33. S1099–S1099. 2 indexed citations

Al-Batran, Salah-Eddin, Sylvie Lorenzen, Peter Thuss‐Patience, et al.. (2022). Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.. Journal of Clinical Oncology. 40(16_suppl). 4003–4003. 70 indexed citations

Al-Batran, S-E., Sylvie Lorenzen, Nils Homann, et al.. (2021). 1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK. Annals of Oncology. 32. S1069–S1069. 22 indexed citations

Stein, Alexander, Lisa Paschold, Joseph Tintelnot, et al.. (2021). LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217). Annals of Oncology. 32. S1331–S1331. 9 indexed citations

10.

Kopp, Christina, Sylvie Lorenzen, Timo Gaiser, et al.. (2021). 1430P Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK. Annals of Oncology. 32. S1069–S1070. 2 indexed citations

11.

Pauligk, Claudia, Peter Thuss‐Patience, Jorge Riera‐Knorrenschild, et al.. (2020). 1443P Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO. Annals of Oncology. 31. S908–S908. 6 indexed citations

12.

Vogel, Arndt, Gabriele Margareta Siegler, Jürgen Siebler, et al.. (2020). 988P Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC. Annals of Oncology. 31. S691–S691. 2 indexed citations

13.

Tintelnot, Joseph, Eray Goekkurt, Mascha Binder, et al.. (2020). Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer. 20(1). 503–503. 24 indexed citations

14.

Sinn, M., Torsten Liersch, Hanno Riess, et al.. (2020). CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results. European Journal of Cancer. 138. 172–181. 22 indexed citations

15.

Schmalenberg, Harald, Salah‐Eddin Al‐Batran, Claudia Pauligk, et al.. (2017). CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach. Journal of Cancer Research and Clinical Oncology. 144(3). 559–569. 5 indexed citations

16.

Al-Batran, S-E., Claudia Pauligk, Nils Homann, et al.. (2017). Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Annals of Oncology. 28. v616–v616. 16 indexed citations

17.

Hofheinz, Ralf‐Dieter, K Borchert, Albrecht Kretzschmar, et al.. (2017). Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.. Journal of Clinical Oncology. 35(15_suppl). TPS4133–TPS4133. 9 indexed citations

18.

Rachow, Tobias, Sibylle Bremer-Streck, Udo Lindig, et al.. (2017). Measurement of piperacillin plasma concentrations in cancer patients with suspected infection. Infection. 45(5). 629–636. 2 indexed citations

19.

Fensterer, H, Carmen Schade‐Brittinger, Hans‐Helge Müller, et al.. (2013). Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Annals of Oncology. 24(10). 2576–2581. 28 indexed citations

20.

Wagner, Dorothea, A. Wein, Harald Schmalenberg, et al.. (2006). Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Annals of Oncology. 18(1). 82–87. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact